Key facts
- It has raised $3.5M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Novo Holdings, Business Finland, Aalto Start-Up Center, Imbestio Capital, Incate — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Arivin Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Arivin Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arivin Therapeutics
Operator of a biotech company intended to develop anti-toxin strategies to address antimicrobial resistance. The company's approach targets bacterial toxins and biofilms, reducing inflammation and strengthening the immune system, enabling healthcare industries to avoid resistance development, a major challenge in traditional antibiotic therapy.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Employees
- 9
- Website
- arivintx.com/
- Ownership
- Privately Held (backing)
Arivin Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arivin Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arivin Therapeutics in its N-PORT filings yet. We sweep new filings monthly.